Mike McMullen, Agilent Technologies CEO

Up­dat­ed: Ag­i­lent throws down $725M to dou­ble man­u­fac­tur­ing ca­pac­i­ty for nu­cle­ic acids to meet API de­mand

A life sci­ence CD­MO is in­vest­ing hun­dreds of mil­lions of dol­lars in­to man­u­fac­tur­ing nu­cle­ic acids amid in­creas­ing de­mand for ac­tive phar­ma­ceu­ti­cal in­gre­di­ents, or API.

Ag­i­lent Tech­nolo­gies, which spun out of Amer­i­can tech gi­ant Hewlett Packard back in 1999, put the word out on Mon­day, say­ing that the $725 mil­lion will be used to dou­ble the com­pa­ny’s cur­rent man­u­fac­tur­ing ca­pac­i­ty for ther­a­peu­tic nu­cle­ic acids. These nu­cle­ic acids, al­so known as ther­a­peu­tic oligonu­cleotides, are DNA or RNA mol­e­cules that act as the API for cer­tain drugs that tar­get in­di­ca­tions such as can­cer or rare dis­eases.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.